# CagriSema (cagrilintide + semaglutide)

Source: https://aminodesk.com/library/cagrisema
Publisher: Amino Desk
Updated: 2026-11-17
Clinical review: pending

CagriSema is Novo Nordisk's once-weekly injection that combines semaglutide with cagrilintide, an amylin drug. Its main trial showed about 20% weight loss. It is under FDA review and was not approved when we last checked, in November 2026.

- **Legal lane:** investigational. Under FDA review; not approved.
- **Evidence grade:** B. Large Phase 3 trials, not yet approved.
- **Form:** weekly injection under the skin
- **What is in it:** cagrilintide 2.4 mg and semaglutide 2.4 mg at the trial target dose

## What it is

A fixed combination of two drugs made by the manufacturer: [semaglutide](https://aminodesk.com/library/semaglutide), the GLP-1 in Wegovy, and [cagrilintide](https://aminodesk.com/library/cagrilintide), which acts on the amylin receptor. Unlike the seller blends elsewhere in this library, this combination has been tested as a single product in large trials.

## What the evidence shows

In REDEFINE 1, the main trial, average weight loss was 20.4%, or 22.7% counting only people who stayed on treatment. The trial included groups on cagrilintide alone and semaglutide alone, and the combination beat both.

Two results temper that. The 20.4% figure was below what analysts had expected, and a head-to-head trial against tirzepatide, reported in February 2026, was described in coverage as a loss for CagriSema.

## Legal status

- Novo Nordisk submitted its application to the FDA on December 18, 2025, based on REDEFINE 1 and REDEFINE 2.
- The company said it expected a decision in the last quarter of 2026. As of early November 2026, no decision had been announced.
- The company has said a US launch is planned for early 2027 if it is approved.
- Until then it cannot be prescribed. The FDA has said cagrilintide cannot be compounded.

This status changes on a single announcement. Check the date on this page.

## Reported dosing

**No approved dose exists yet.**

The Phase 3 trials worked up to a target of 2.4 mg of each drug once a week. If the FDA approves it, the label will set the schedule.

## Safety

- Stomach side effects, the same kind seen with semaglutide, were the most common in trials.
- Semaglutide carries a boxed warning about thyroid C-cell tumors seen in rodents. Whether and how that appears on a CagriSema label is for the FDA to decide.
- Anything sold now as CagriSema or as cagrilintide has no regulated source.

## Common questions

### Is CagriSema FDA-approved?

Not when we last checked, in early November 2026. It was under review, with a decision expected by the end of 2026.

### How much weight did people lose on CagriSema?

20.4% on average in the REDEFINE 1 trial, or 22.7% among people who stayed on treatment.

### What is in CagriSema?

Cagrilintide and semaglutide, combined in one weekly injection.

### Can CagriSema be compounded?

No. The FDA has said cagrilintide cannot be compounded.

## Sources

- [Remy Research: CagriSema approval status, updated November 6, 2026](https://remyresearch.com/research/is-cagrisema-approved)
- [PepGLP1: status as of November 3, 2026, and filing date](https://pepglp1.com/cagrisema-fda-approval/)
- [Healthline: CagriSema results and FDA timeline](https://www.healthline.com/health/drugs/cagrisema-for-weight-loss)
- [GLP Finders: REDEFINE results and the head-to-head trial against tirzepatide](https://glpfinders.com/medications/cagrisema)
- [VialHelp: what the application is based on](https://vialhelp.com/2026/08/14/cagrisema-fda-review-decision-late-2026/)

---
Educational information from Amino Desk (aminodesk.com), not medical advice. Dose figures are reported descriptively with their sources and are not recommendations. Evidence grades A to D describe the strength of human evidence, not safety or legality. When you use this content, cite the page URL.
